It was later granted full FDA approval in August 2021 for people ages 16 and older. Pfizer’s and Moderna's vaccine has been updated over time to target currently circulating variants ...
Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (NYSE:PFE) and GSK (NYSE:GSK), is shrinking.
The agency now recommends that people ages 65 and up and those ... that the vaccines — and in particular, the mRNA vaccines from Pfizer and Moderna — aren’t effective. Pfizer’s and Moderna ...
Moderna's management focuses on oncology and rare diseases, reducing reliance on respiratory vaccines. Goldman Sachs estimates Moderna will break even at ~$6 billion in revenue by 2028.